• Explore /
  • Poster
  • / Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).

Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).

Abstract Poster

Authors

Daniel Catenacci

Daniel V.T. Catenacci

University of Chicago Pritzker School of Medicine, Chicago, IL

Daniel V.T. Catenacci , Haeseong Park , A. Craig Lockhart , Philip Jordan Gold , Peter C. Enzinger , Jeffrey L. Nordstrom , Sam Hong , Howard S. Hochster , Ronan Joseph Kelly , Hope Elizabeth Uronis , Johanna C. Bendell , Sang Cheul Oh , Se Hoon Park , Yeul Hong Kim , Yoon-Koo Kang , Keun-Wook Lee , Matthew CH Ng , Jon M. Wigginton , Jan Kenneth Davidson-Moncada , Yung-Jue Bang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02689284

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 140)

DOI

10.1200/JCO.2018.36.4_suppl.140

Abstract #

140

Poster Bd #

J21

Abstract Disclosures

Similar Posters

First Author: Daniel V.T. Catenacci

First Author: Daniel V.T. Catenacci

First Author: Daniel V.T. Catenacci

First Author: Timothy Jay Price